Iradimed ups dividend, sets 2026 guidance, launch schedule
Iradimed posts record Q4 2025 results above prior guidance (EPS $0.54 on $22.7M revenue), raises its quarterly dividend 18% to $0.20, issues FY2026 and Q1 2026 guidance (Q1 EPS $0.44–$0.48 on $21–$22M), and sets up the 3870 pump launch aimed at driving 2026 revenue above $100M.
- Eighteenth consecutive record revenue quarter; Q4 revenue $22.7M, up 17% YoY, above guidance.
- Q4 GAAP EPS $0.50 and non-GAAP $0.54, both up low‑20s percent YoY.
- Full-year 2025 revenue $83.8M, up 14% YoY; GAAP EPS $1.75, non-GAAP $1.93.
- 3870 MR IV pump launch is key growth driver, targeting $100M+ annual revenue run rate in 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.